Suppliers and packagers for generic pharmaceutical drug: CAPMATINIB HYDROCHLORIDE

CAPMATINIB HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis Pharm	TABRECTA	capmatinib hydrochloride	TABLET;ORAL	213591	NDA	Novartis Pharmaceuticals Corporation	0078-0709-56	56 TABLET, FILM COATED in 1 BOTTLE (0078-0709-56)	2020-05-06
Novartis Pharm	TABRECTA	capmatinib hydrochloride	TABLET;ORAL	213591	NDA	Novartis Pharmaceuticals Corporation	0078-0709-94	56 TABLET, FILM COATED in 1 BOTTLE (0078-0709-94)	2020-05-06
Novartis Pharm	TABRECTA	capmatinib hydrochloride	TABLET;ORAL	213591	NDA	Novartis Pharmaceuticals Corporation	0078-0716-56	56 TABLET, FILM COATED in 1 BOTTLE (0078-0716-56)	2020-05-06
Novartis Pharm	TABRECTA	capmatinib hydrochloride	TABLET;ORAL	213591	NDA	Novartis Pharmaceuticals Corporation	0078-0716-94	56 TABLET, FILM COATED in 1 BOTTLE (0078-0716-94)	2020-05-06

CAPMATINIB HYDROCHLORIDE SUPPLIERS: MARKET LANDSCAPE AND OPERATIONAL CONSIDERATIONS

Last updated: February 19, 2026

This analysis identifies key suppliers for Capmatinib Hydrochloride, a targeted therapy for non-small cell lung cancer. The report details their manufacturing capabilities, regulatory standing, and potential supply chain risks.

WHO ARE THE PRIMARY MANUFACTURERS AND DISTRIBUTORS OF CAPMATINIB HYDROCHLORIDE?

The global supply of Capmatinib Hydrochloride is concentrated among a limited number of active pharmaceutical ingredient (API) manufacturers and specialized chemical suppliers. These entities operate under stringent regulatory oversight to ensure product quality and consistency.

• Direct API Manufacturers: These companies are involved in the synthesis of Capmatinib Hydrochloride API. They often possess advanced chemical synthesis capabilities and adhere to Good Manufacturing Practices (GMP).

  • Novartis AG: As the originator of the drug (marketed as Tabrecta), Novartis is a primary source of Capmatinib Hydrochloride for its finished dosage form manufacturing. Their internal production or contracted manufacturing organizations (CMOs) represent a significant portion of the global supply.
  • Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs): A number of specialized CMOs and CDMOs globally possess the technical expertise and regulatory approvals to produce complex APIs like Capmatinib Hydrochloride. Identification of specific CMOs contracted by Novartis or for generic development requires direct engagement with these entities or proprietary supply chain intelligence. However, companies with experience in complex heterocyclic synthesis and chiral chemistry are likely candidates. Examples of firms with broad API manufacturing capabilities include Lonza, Catalent, and Siegfried AG. These are indicative of the types of organizations that could be involved, rather than confirmed suppliers of this specific API.

• Chemical Suppliers (Intermediates and Raw Materials): While not directly supplying the finished Capmatinib Hydrochloride API, these suppliers provide critical precursor chemicals and intermediates necessary for its synthesis. The security of the Capmatinib Hydrochloride supply chain is contingent on the reliability of these upstream suppliers.

  • Specialty Chemical Companies: Companies specializing in the synthesis of complex organic molecules, such as substituted indazoles, pyrrolopyrimidines, and fluorinated aromatic compounds, are key contributors. These can include both large chemical conglomerates and smaller, niche manufacturers.
  • Research Chemical Suppliers: For smaller-scale or early-stage research and development needs, suppliers like Sigma-Aldrich (Merck KGaA), TCI America, and Alfa Aesar offer Capmatinib Hydrochloride or its advanced intermediates, albeit typically in research quantities and not for commercial pharmaceutical production.

WHAT ARE THE REGULATORY REQUIREMENTS FOR CAPMATINIB HYDROCHLORIDE PRODUCTION?

The production of Capmatinib Hydrochloride for pharmaceutical use is subject to rigorous regulatory frameworks enforced by health authorities worldwide. Compliance with these standards is mandatory for market access.

• Good Manufacturing Practices (GMP):

  • US Food and Drug Administration (FDA): Manufacturers must adhere to current GMP (cGMP) regulations as outlined in 21 CFR Parts 210 and 211. Facilities are subject to regular FDA inspections.
  • European Medicines Agency (EMA): Compliance with EU GMP guidelines is required. Inspections are conducted by national competent authorities within EU member states.
  • Other Regulatory Bodies: Equivalent GMP standards are enforced by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, Health Canada, and the Therapeutic Goods Administration (TGA) in Australia.

• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):

  • API manufacturers typically file DMFs (in the US) or ASMFs (in Europe) with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API.
  • Purpose: They allow regulatory authorities to review API manufacturing without disclosing proprietary information to the drug product manufacturer.

• Quality Control and Analytical Testing:

  • Specifications: API must meet predefined specifications for identity, purity, strength, and quality. This includes limits for related substances, residual solvents, and heavy metals.
  • Analytical Methods: Validated analytical methods, such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), are essential for quality testing.

• ICH Guidelines:

  • The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are critical. Key guidelines include:
    • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
    • ICH Q1A-Q1F: Stability testing of new drug substances and products.
    • ICH Q3A-Q3E: Impurities in new drug substances and drug products.

WHAT ARE THE KEY OPERATIONAL CONSIDERATIONS FOR SECURING CAPMATINIB HYDROCHLORIDE SUPPLY?

Supply chain reliability for Capmatinib Hydrochloride necessitates a multi-faceted approach, encompassing supplier qualification, risk mitigation, and strategic sourcing.

• Supplier Qualification Process:

  • Audits: Comprehensive on-site audits of manufacturing facilities are critical to verify GMP compliance, quality systems, and production capabilities.
  • Technical Capabilities Assessment: Evaluation of the supplier's synthetic route, process validation data, impurity profiling, and scale-up capacity.
  • Regulatory Compliance: Review of the supplier's regulatory history, DMF/ASMF status, and inspection records from relevant health authorities.
  • Financial Stability and Business Continuity: Assessment of the supplier's financial health and their plans for business continuity in case of disruptions.

• Supply Chain Risk Mitigation:

  • Geopolitical Risks: Reliance on suppliers in regions prone to political instability, trade disputes, or natural disasters poses a significant risk. Diversification of suppliers across different geographical locations is advisable.
  • Raw Material Sourcing: Understanding the upstream supply chain for key starting materials and intermediates is crucial. Dependence on single-source raw material suppliers can create vulnerabilities.
  • Intellectual Property (IP) and Security: Ensuring robust IP protection measures are in place for proprietary synthesis routes and formulations, especially when engaging with contract manufacturers.
  • Logistics and Transportation: Secure and temperature-controlled transportation is vital to maintain API integrity. Delays in customs, transit, or adverse environmental conditions during shipping can impact product quality.

• Strategic Sourcing and Inventory Management:

  • Dual Sourcing: Establishing relationships with at least two qualified suppliers can significantly reduce the risk of supply interruption. This requires careful management to avoid diluting supplier commitment.
  • Inventory Buffers: Maintaining strategic inventory levels of API and critical intermediates can help buffer against short-term supply disruptions. This must be balanced against holding costs and shelf-life considerations.
  • Long-Term Contracts: Negotiating long-term supply agreements with key suppliers can ensure price stability and guaranteed supply volume, provided robust performance clauses are included.

WHAT ARE THE EMERGING TRENDS IN CAPMATINIB HYDROCHLORIDE MANUFACTURING AND SUPPLY?

The pharmaceutical API manufacturing landscape is continuously evolving, with several trends impacting the production and supply of complex molecules like Capmatinib Hydrochloride.

• Advancements in Synthetic Chemistry:

  • Flow Chemistry: Continuous manufacturing processes, utilizing flow chemistry, offer advantages in terms of efficiency, safety, and scalability for complex multi-step syntheses. This can lead to reduced waste and improved control over reaction parameters.
  • Biocatalysis and Enzymatic Synthesis: The use of enzymes for specific synthetic transformations can offer improved selectivity, milder reaction conditions, and reduced environmental impact compared to traditional chemical catalysts.
  • Process Analytical Technology (PAT): Implementation of PAT tools allows for real-time monitoring and control of manufacturing processes, leading to enhanced product consistency and reduced batch failures.

• Globalization and Regionalization of Supply Chains:

  • While global sourcing has been prevalent, recent disruptions have prompted a re-evaluation of supply chain resilience. This may lead to increased regionalization of manufacturing for critical APIs, reducing reliance on single geographical hubs.
  • Onshoring/Nearshoring: Pharmaceutical companies may explore onshoring or nearshoring manufacturing capabilities to mitigate risks associated with long, complex global supply chains.

• Sustainability and Green Chemistry Initiatives:

  • Increasing pressure from regulatory bodies and public demand is driving the adoption of greener manufacturing practices. This includes reducing solvent usage, minimizing waste generation, and developing more energy-efficient processes.
  • Suppliers are increasingly evaluated on their environmental, social, and governance (ESG) performance.

• Digitalization and Data Analytics:

  • The application of big data analytics, artificial intelligence (AI), and machine learning (ML) can optimize manufacturing processes, predict potential supply chain disruptions, and improve quality control.
  • Digitalization of quality management systems and supply chain tracking enhances transparency and traceability.

KEY TAKEAWAYS

• The supply of Capmatinib Hydrochloride API is primarily controlled by originator companies and specialized CMOs/CDMOs with advanced synthesis capabilities and stringent regulatory compliance.
• Adherence to global GMP standards, supported by comprehensive DMFs/ASMFs, is a non-negotiable requirement for all manufacturers.
• Supply chain strategy must prioritize supplier qualification, robust risk mitigation (including dual sourcing and geopolitical diversification), and strategic inventory management.
• Emerging trends in synthetic chemistry (flow chemistry, biocatalysis), supply chain regionalization, and sustainability are shaping the future of API manufacturing.

FREQUENTLY ASKED QUESTIONS

1. What is the typical lead time for API orders of Capmatinib Hydrochloride from qualified manufacturers? Lead times for API orders can vary significantly depending on the manufacturer's current production schedule, batch size, and contractual agreements. However, for commercial quantities, lead times typically range from 3 to 9 months. This includes time for manufacturing, quality control release, and shipping.

2. Are there any specific patent expirations relevant to Capmatinib Hydrochloride that could impact supplier dynamics? The primary patents covering the composition of matter and methods of use for Capmatinib are held by Novartis. While specific patent expiration dates are subject to jurisdiction and potential extensions (e.g., patent term extensions), generic entry would generally commence after the expiry of these core patents, which would then likely broaden the supplier landscape. A detailed patent landscape analysis is recommended for precise timing.

3. What are the main challenges in qualifying a new supplier for Capmatinib Hydrochloride API? Key challenges include the high cost and time associated with GMP audits, the need for extensive process validation and comparability studies, ensuring consistent quality across batches, and meeting stringent regulatory requirements for DMF/ASMF filings. Furthermore, the proprietary nature of some synthesis routes may limit the number of technically capable and willing suppliers.

4. How does the stability of Capmatinib Hydrochloride API affect its supply chain and storage requirements? Capmatinib Hydrochloride is generally considered a stable API when stored under recommended conditions, typically protected from light and moisture at controlled room temperatures. However, long-term stability data from the manufacturer is crucial. Supply chain management must ensure that transportation and storage conditions prevent degradation, which could involve temperature-controlled logistics and appropriate packaging.

5. What is the typical purity level required for pharmaceutical-grade Capmatinib Hydrochloride API? Pharmaceutical-grade Capmatinib Hydrochloride API typically requires a purity of not less than 98.0% or 99.0%, with strict limits on individual impurities, residual solvents, and heavy metals as defined by pharmacopeial monographs (if available) or the drug product's registered specifications. These specifications are detailed within the manufacturer's DMF/ASMF.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website]